Frederick Lansigan

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 645 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

Adam M. Petrich, Mitul Gandhi, Borko Jovanovic et al. · Blood · 2014 · 466 citations

Medicine, Oncology, Hematologic Oncology +9

Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission

Daniel J. Landsburg, Marissa K. Falkiewicz, Joseph Maly et al. · Journal of Clinical Oncology · 2017 · 174 citations

Medicine, Oncology, Cell Therapy +11

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States

Anthony R. Mato, Meghan C. Thompson, John N. Allan et al. · Haematologica · 2018 · 165 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study

Steven I. Park, Steven M. Horwitz, Francine M. Foss et al. · Cancer · 2019 · 146 citations · Full text

Medicine, Oncology, Cancer Immunology +9